ArticleAgents and actions1989
Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice.
Article in Agents and actions, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 57 citations in OpenAlex.
- Inhibitory Effect of Paquinimod on a Murine Model of Neutrophilic Asthma Induced by Ovalbumin with Complete Freund's Adjuvant.Canadian respiratory journal · 2021Article
- Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.Mucosal immunology · 2016Review
- S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.Arteriosclerosis, thrombosis, and vascular biology · 2015Review
- S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.Mediators of inflammation · 2013Review
- Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.PLoS biology · 2009Article
- Interleukin-10 mediates the protective effect of Linomide by reducing CXC chemokine production in endotoxin-induced liver injury.British journal of pharmacology · 2004Article
- Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses.Clinical and experimental immunology · 1999Article
- Studies on the contribution of c-fos/AP-1 to arthritic joint destruction.The Journal of clinical investigation · 1997Article
- Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.Diabetologia · 1994Article
- Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice.Agents and actions · 1993Article
- Anti-inflammatory properties of zinc protoporphyrin disodium (Zn-PP-2Na).Agents and actions · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The quinoline-3-carboxamide, Linomide, has been shown to possess potent immunomodulatory activity. We have evaluated the effect of Linomide in the type II collagen induced arthritis in mice. Treatment with Linomide (1.25-80 mg/kg/day) from the day of immunization strongly suppressed the arthritic response. On the other hand, initiation of treatment (20-80 mg/kg/day) at the onset of arthritis resulted in an increased severity of the arthritis. These potent and contradictory effects of Linomide, depending on treatment regime, indicates that central immuno-regulatory functions are affected and that this compound may be a useful tool for the understanding of autoimmune mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.